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Abstract
Introduction: Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell
carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we
do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies
are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare
histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an
important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown
to have significant clinical benefit in advanced renal cell carcinoma.
Case presentation: We present the case of a 43-year-old Caucasian man with advanced chromophobe renal cell
carcinoma treated with the tyrosine kinase inhibitor sunitinib and subsequently with sorafenib and the mammalian
target of the rapamycin inhibitor everolimus, achieving a prolonged response and significant clinical benefit. We
report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic
chromophobe renal cell carcinoma.
Conclusions: Up to now, no published data from randomized clinical studies have addressed the question of
efficacy of everolimus as a third-line treatment after failure of tyrosine kinase inhibitors. To the best of our
knowledge, this case is the first report of chromophobe renal cell carcinoma treated successfully with sequential
tyrosine kinase and mammalian target of rapamycin inhibitor therapy. Notably, the time on treatment with
sunitinib exceeded four years. The case presented here implies that everolimus could be a viable option for
patients with metastatic chromophobe renal cell carcinoma.
Introduction
Renal cell carcinoma (RCC) accounts for approximately
1% of all cancers, and the incidence of kidney cancer,
unlike other genitourinary malignancies, is rapidly increas-
ing at 2.5% per year. Chromophobe RCC (ChRCC) repre-
sents 5% of neoplasms of renal tubular epithelium.
ChRCC is a distinct type of renal cancer, is presumably
derived from the intercalated cells of the collecting duct
system, and exhibits a better prognosis than other types of
RCC.
An enhanced understanding of the underlying biology
of RCC has led to systemic therapy targeted at the vascu-
lar endothelial growth factor (VEGF) pathway as well as
the the mammalian target of the rapamycin (mTOR)
pathway. Agents blocking these pathway elements have
demonstrated robust efficacy, offer new strategic options
for patients with metastatic RCC, and have largely
replaced cytokines as the standard of care in this disease.
Trials with small-molecule VEGF and platelet-derived
growth factor (PDGF) receptor inhibitors, such as suniti-
nib and sorafenib, have shown significant clinical activity
in randomized trials in advanced clear cell RCC
(CCRCC). Both drugs have been approved by the US
Food and Drug Administration for the treatment of
metastatic RCC. Data regarding the activity of sunitinib
and sorafenib in advanced ChRCC are lacking because
recent trials were restricted mostly to patients with
CCRCC. * Correspondence: vmichalaki@usa.net
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had ChRCC and who experienced improvement in his
general condition and stable disease on treatment with
everolimus after a prolonged response to sunitinib treat-
ment. This case report suggests that everolimus is an
effective and appropriate treatment for this RCC tumor
subtype.
Case presentation
A 43-year-old Caucasian man presented with painless
macroscopic hematuria of sudden onset and gradual
deterioration. Ultrasound of his kidneys demonstrated a
mass lesion with abnormal echogenicity and vasculariza-
tion in the upper pole of his right kidney.
A computed tomography scan of the retroperitoneal
space showed a malignant space-occupying mass in the
upper pole of his right kidney. He underwent right radical
nephrectomy in 2003. The nephrectomy specimen showed
a 20 × 12 × 8 cm tumor at the upper pole with a homoge-
nous, solid light brown cut surface. The tumor was limited
to his kidney. The sections stained by hematoxylin and
eosin showed sheets of polygonal cells with abundant
granular eosinophilic cytoplasm with oval nuclei, convo-
luted nuclear membranes, and perinuclear cytoplasmic
vacuolization. Histology revealed ChRCC.
Three years after nephrectomy, a routine abdominal
scan showed a recurrence in his liver (Figure 1) and in
bones in the chest area. The disease was considered
advanced, and sunitinib 50 mg once daily on the 4/2 sche-
dule (four weeks on treatment and two weeks off treat-
ment cycle) was commenced. He also started zoledronic
acid infusions and was treated with CyberKnife
® for bone
metastases. A dose reduction to 37.5 mg after three
months for gastrointestinal adverse effects was necessary.
Our patient had a partial response to treatment and had a
maximum response at nine months (Figure 2). Sunitinib
was continued for four years despite some increase in
bone disease burden but was stopped at 50 months as a
consequence of disease progression in his liver. Sorafenib
800 mg daily was started after cessation of sunitinib for
progressive disease. Follow-up imaging demonstrated
stable disease. However, the next follow-up, three months
later, showed progressive disease in his liver and bones.
Everolimus 10 mg daily was started. At the time of this
report, five months after the commencement of everoli-
mus, there is radiologic evidence (Figure 3) of ongoing
incremental reduction in liver disease volume, and our
patient feels well and is tolerating treatment with no sig-
nificant toxicity.
To the best of our knowledge, this case is the first
report of ChRCC treated successfully with sequential
tyrosine kinase and mTOR inhibitor therapy. Notably,
the time on treatment with sunitinib exceeded four
years.
Figure 1 An abdominal scan shows recurrence in the liver (multiple lesions).
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Figure 3 Incremental reduction in liver disease volume on treatment with everolimus.
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RCC treatment has been classically derived from clinical
trials that incorporated all histologies comprising clear
cell, papillary, chromophobe, and other rarer subtypes.
Most recently, novel therapies (sunitinib and sorafenib)
have shown significant clinical activity in advanced RCC
and have changed the standard of care in this disease
[1-3]. However, pivotal studies with these drugs were
performed exclusively in patients with clear cell histol-
ogy. Therefore, the optimal therapy for papillary and
chromophobe histologies remains unknown. Overall,
ChRCC is considered to portend a good prognosis and
is associated with earlier-stage tumors and longer overall
survival in comparison with CCRCC. There are conflict-
ing reports on prognosis in metastatic disease, and few
data on response to treatment exist. Increased VEGF-6
and c-Kit (i.e., mast/stem cell growth factor receptor;
proto-oncogene c-Kit; tyrosine-protein kinase Kit; or
CD117) expressions have been reported in ChRCC, but
the relevance of this to treatment is unknown [4-6]. In
an expanded-access trial of sunitinib, 13% of patients
had non-clear cell histology, and there was evidence of
clinical activity in this group [7]. A large international
study reported the outcome of 1001 patients with meta-
static RCC (82 of whom had papillary histology). Five-
year survival rates of papillary and clear cell subtypes
were similar (about 10%). No treatment has proven to
be active in papillary RCC, unlike CCRCC. One recently
published series illustrated a response rate of only 5% in
patients treated with these VEGF-targeted therapies [8].
Both responders received sunitinib, corresponding to an
overall response rate of 17% in sunitinib-treated
patients. Similarly, progression-free survival seemed to
be longer in the patients treated with sunitinib in com-
parison with the patients treated with sorafenib (11.9
versus 5.1 months, respectively).
IIt is interesting to note that several patients who
experienced progression on one anti-VEGF therapy and
who were subsequently switched to another anti-VEGF
therapy achieved substantial response. Although the
overall duration of follow-up was relatively short, the
results support the clinical rationale for continued tar-
geting of the VEGF and c-Kit signaling pathways in
non-clear cell RCC [9,10]. A phase III trial of temsiroli-
mus also included patients with non-clear cell histology,
and a subgroup analysis demonstrated an improved
overall survival on temsirol i m u si nc o m p a r i s o nw i t h
interferon and the combination of both drugs [11].
Choueiri and colleagues [12] retrospectively reviewed
the efficacies of sunitinib and sorafenib in patients with
metastatic papillary RCCs and ChRCCs. Seven patients
with ChRCC were treated with sunitinib, and five were
treated with sorafenib. A partial response occurred in
three patients (25%), and the median progression-free
survival time for patients with ChRCC was 10.6 months
[12]. In summary, these data suggest that sunitinib and
s o r a f e n i bh a v es o m ea c t i v i t yi nC h R C C .T ot h eb e s to f
our knowledge, there are no published reports of the
use of the mTOR inhibitors in this setting.
Conclusions
In this report, we describe the case of a patient who had
ChRCC and who experienced improvement in his gen-
eral condition and stable disease on treatment with
everolimus after a prolonged response to sunitinib treat-
ment. This case report suggests that anti-VEGF agents
such as sunitinib and mTOR-targeted agents such as
everolimus are effective and appropriate treatments for
this RCC tumor subtype.
Now that agents directed against these pathways have
largely replaced immunotherapy as the standard of care,
new questions have emerged and are the subject of
ongoing clinical trials. Additional prospective studies
and clinical experience with this rare histologic non-
clear cell subtype are needed.
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